Nasdaq Cocp News Today

Cocrystal Pharma, Inc. (NASDAQ:COCP – Get Free Report) was the recipient of a significant decline in short interest in January. As of January 15th, there was short interest totalling 800 shares, a decline of 20.0% from the December 31st total of 1,000 shares. Approximately 0.0% of the company’s stock are sold short. Based on an […]

Cocrystal Pharma, Inc. (NASDAQ:COCP – Get Free Report) was the target of a large decline in short interest in the month of December. As of December 31st, there was short interest totalling 1,000 shares, a decline of 63.0% from the December 15th total of 2,700 shares. Approximately 0.0% of the shares of the company are […]

Cocrystal Pharma (NASDAQ:COCP – Free Report) had its price target decreased by HC Wainwright from $12.00 to $10.00 in a research report released on Wednesday, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Cocrystal Pharma’s Q4 2023 earnings at ($0.58) EPS, FY2023 earnings at ($2.01) […]

Cocrystal Pharma (NASDAQ:COCP – Get Free Report) and Mersana Therapeutics (NASDAQ:MRSN – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership. Volatility and Risk Cocrystal Pharma has a […]

HC Wainwright restated their buy rating on shares of Cocrystal Pharma (NASDAQ:COCP – Free Report) in a report published on Monday, Benzinga reports. HC Wainwright currently has a $12.00 price target on the stock. HC Wainwright also issued estimates for Cocrystal Pharma’s Q4 2023 earnings at ($0.59) EPS, FY2023 earnings at ($2.03) EPS, Q1 2024 […]

Cocrystal Pharma, Inc. (NASDAQ:COCP – Get Free Report) was the target of a large decline in short interest in September. As of September 15th, there was short interest totalling 7,100 shares, a decline of 51.4% from the August 31st total of 14,600 shares. Approximately 0.1% of the company’s shares are short sold. Based on an […]

Cocrystal Pharma, Inc. (NASDAQ:COCP – Free Report) – Research analysts at HC Wainwright increased their Q3 2023 earnings per share (EPS) estimates for Cocrystal Pharma in a research report issued on Tuesday, August 15th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($0.45) for the quarter, up […]

Cocrystal Pharma (NASDAQ:COCP – Get Rating) had its price objective lowered by HC Wainwright from $35.00 to $12.00 in a research note released on Wednesday morning, The Fly reports. HC Wainwright also issued estimates for Cocrystal Pharma’s Q2 2023 earnings at ($0.58) EPS, Q3 2023 earnings at ($0.54) EPS, Q4 2023 earnings at ($0.56) EPS, […]

Cocrystal Pharma, Inc. (NASDAQ:COCP – Get Rating) was the target of a large growth in short interest in March. As of March 31st, there was short interest totalling 5,000 shares, a growth of 163.2% from the March 15th total of 1,900 shares. Based on an average daily volume of 84,700 shares, the short-interest ratio is […]

Cocrystal Pharma, Inc. (NASDAQ:COCP – Get Rating) Director Phillip Md Et Al Frost purchased 1,015,229 shares of the stock in a transaction that occurred on Tuesday, April 4th. The stock was acquired at an average cost of $1.97 per share, for a total transaction of $2,000,001.13. Following the completion of the acquisition, the director now […]